Trump ups the stakes with 'granddaddy of them all' drug pricing executive order. But he could be running out of time

Amber Tong

When President Donald Trump signed four executive orders in late July aiming at lowering drug prices, details of the most controversial — “the granddaddy of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Trump ups the stakes with 'granddaddy of them all' drug pricing executive order. But he could be running out of time

Amber Tong

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?

Trump ups the stakes with 'grand­dad­dy of them al­l' drug pric­ing ex­ec­u­tive or­der. But he could be run­ning out of time

Amber Tong

Sign up to read this article for free.

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Trump ups the stakes with 'granddaddy of them all' drug pricing executive order. But he could be running out of time

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Are programs with compounded GLP-1s safe for your population?